Efficacy and safety of drospirenone as a progestin‐only pill in Japanese women: A phase III study
Journal of Obstetrics and Gynaecology Research · 2025
DOI: 10.1111/jog.16340 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2025. Verfasst von Kunio Kitamura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Japan Family Planning Association, Tokyo, Japan. Hauptthemen laut MEDLINE: Androstenes, Mineralocorticoid Receptor Antagonists, Progestins. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ASKA Pharmaceutical Co., Ltd..
Abstract (Originalsprache)
Aim
To evaluate the efficacy and safety of 4 mg of drospirenone (DRSP), a progestin‐only pill (POP), for contraception in Japanese women.
Methods
This was a multicenter, open‐label, single‐arm study. The dosing period of DRSP was 13 cycles, each lasting for 28 days. In one cycle, 4 mg of DRSP was administered orally once daily for the first 24 days, followed by a placebo for 4 days.
Results
Data from 276 subjects were analyzed, with a total of 3319 DRSP exposure cycles. Pregnancy occurred in one subject. The overall Pearl Index [95% CI] was 0.39 [0.01, 2.18], and the cumulative pregnancy rate [95% CI] was 0.40% [0.06, 2.81]. Of the 276 subjects, 273 (98.9%) experienced treatment‐emergent adverse events (TEAEs) and 264 (95.7%) experienced adverse drug reactions. All TEAEs were mild or moderate, with no severe events. The most common TEAE was intermenstrual bleeding (irregular uterine bleeding) (89.5%). Although 31.9% of the subjects had risk factors for venous thromboembolism (VTE), no VTE‐related TEAEs were observed. The incidence of unscheduled bleeding [95% CI] across all cycles was 91.6% [87.7, 94.3].
Conclusions
DRSP, the first POP in Japan, is effective and safe as a contraceptive in Japanese women. It provides a new contraceptive option for Japanese women, including those at risk of VTE for whom combined oral contraceptives are contraindicated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Japan Family Planning Association, Tokyo, Japan.
- Research and Development Department, Exeltis, Madrid, Spain.
- Clinical Development Department, ASKA Pharmaceutical Co., Ltd, Tokyo, Japan.
ORCID-Profile: Tomoya Kagawa
Förderung
- ASKA Pharmaceutical Co., Ltd.
Zitieren
APA
Kitamura, K., Colli, E., Kikuyama, R., Kurihara, Y., Azuma, R., & Kagawa, T. (2025). Efficacy and safety of drospirenone as a progestin‐only pill in Japanese women: A phase III study. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.16340
Vancouver
Kitamura K, Colli E, Kikuyama R, Kurihara Y, Azuma R, Kagawa T. Efficacy and safety of drospirenone as a progestin‐only pill in Japanese women: A phase III study. Journal of Obstetrics and Gynaecology Research. 2025. doi:10.1111/jog.16340
BibTeX
@article{Kitamura2025,
author = {Kitamura, Kunio and Colli, Enrico and Kikuyama, Ryoko and Kurihara, Yumiko and Azuma, Rieko and Kagawa, Tomoya},
title = {Efficacy and safety of drospirenone as a progestin‐only pill in Japanese women: A phase III study},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2025},
doi = {10.1111/jog.16340}
}
EUVIMED